Stoke therapeutics, inc. (STOK)
Income statement / Yearly
Dec'19Dec'18
Operating expenses:
Research and development

23,764

8,371

General and administrative

11,914

4,410

Total operating expenses

35,678

12,781

Loss from operations

-35,678

-12,781

Other income:
Interest income

3,351

270

Other income, net

2

-10

Total other income

3,353

260

Net loss and comprehensive loss

-32,325

-12,521

Net loss per share attributable to common stockholders, basic and diluted

-1.80

-17.65

Weighted-average common shares outstanding, basic and diluted

17,971

709